Rare Disease Endpoint Advancement Pilot Program
FDA is establishing a Rare Disease Endpoint Advancement (RDEA) Pilot Program to support novel efficacy endpoint development for drugs that treat rare diseases.
FDA is establishing a Rare Disease Endpoint Advancement (RDEA) Pilot Program to support novel efficacy endpoint development for drugs that treat rare diseases.
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
Guest Editors: Dr Claire Fuller and Dr Anupam Das Deadline: Tuesday, 31 December 2024 Here at Clinical and Experimental Dermatology, we are inviting submissio
Early interventions with hearing aids attenuated the risk
And no, it doesn’t involve doing surgery on the weekends, notes Peter Viccellio, MD
Nationwide findings mirror those from research after Texas banned early pregnancy abortion
Sleep quality in early midlife predicted brain age 15 years later
Significant improvement beyond 100 weeks after single injection of mutation-agnostic MCO-010
Future studies should investigate whether getting montelukast earlier makes a difference
The elective allows new parents to spend time with their child while gaining knowledge
Only 4% reported regret after receiving puberty blockers, gender-affirming hormones